The measurement-problem argument can be partially validated by historical precedent: antibiotics were also difficult to measure precisely in early economic data, yet they produced substantial GDP gains, pharmaceutical sector output gains, and life expectancy improvements; however, AI pharmaceuticals have not yet demonstrated comparable results and life expectancy is not increasing, so the analogy is limited.